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Background:  Pigs  are  natural  hosts  for inﬂuenza  A viruses,  and  the  infection  is  widely  prevalent  in swine
herds throughout  the  world.  Current  commercial  inﬂuenza  vaccines  for pigs  induce  a narrow  immune
response  and  are  not  very  effective  against  antigenically  diverse  viruses.  To  control  inﬂuenza  in  pigs,
the development  of more  effective  swine  inﬂuenza  vaccines  inducing  broader  cross-protective  immune
responses  is needed.  Previously,  we  have  shown  that  a  polyvalent  inﬂuenza  DNA  vaccine  using  vec-
tors  containing  antibiotic  resistance  genes  induced  a  broadly  protective  immune  response  in pigs  and
ferrets  using  intradermal  injection  followed  by electroporation.  However,  this  vaccination  approach  is
not practical  in  large  swine  herds,  and  DNA  vaccine  vectors  containing  antibiotic  resistance  genes  are
undesirable.
Objectives:  To investigate  the immunogenicity  of  an  optimized  version  of  our preceding  polyvalent  DNA
vaccine,  characterized  by  a next-generation  expression  vector  without  antibiotic  resistance  markers  and
delivered  by a convenient  needle-free  intradermal  application  approach.
Methods:  The  humoral  and  cellular  immune  responses  induced  by  three  different  doses  of  the  optimized
DNA  vaccine  were  evaluated  in groups  of ﬁve  to  six  pigs. The  DNA  vaccine  consisted  of  six  selected
inﬂuenza  genes  of  pandemic  origin,  including  internally  expressed  matrix  and  nucleoprotein  and  exter-
nally  expressed  hemagglutinin  and  neuraminidase.
Results:  Needle-free  vaccination  of growing  pigs  with  the optimized  DNA  vaccine  resulted  in  spe-
ciﬁc,  dose-dependent  immunity  down  to  the lowest  dose  (200  g  DNA/vaccination).  Both  the
antibody-mediated  and  the  recall  lymphocyte  immune  responses  demonstrated  high reactivity  against
vaccine-speciﬁc  strains  and  cross-reactivity  to vaccine-heterologous  strains.
Conclusion: The  results  suggest  that polyvalent  DNA  inﬂuenza  vaccination  may  provide  a strong  tool  for
broad protection  against  swine  inﬂuenza  strains  threatening  animal  as  well  as  public  health.  In  addition,
the  needle-free  administration  technique  used  for this  DNA vaccine  will provide  an  easy  and  practical
ale  va
Publisapproach  for  the  large-sc
©  2016  The  Author(s).  
. IntroductionInﬂuenza virus is endemic in pigs and affects the majority of
erds in modern swine production [1]. Reproductive problems,
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together with weight loss and aggravation of secondary infec-
tions, are characteristic of swine inﬂuenza and result in serious
animal welfare problems and economic losses for the swine indus-
try [2]. It is well known that pigs and humans can exchange
inﬂuenza viruses, and a recent example is the triple reassortant
H1N1pdm09, composed of genes from three known swine viruses,
which spread rapidly among humans during the pandemic in 2009
and later transmitted from humans to pigs [3]. Protection of pigs
against inﬂuenza infection by effective vaccination would provide
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
ccine 3
a
h
o
s
t
s
o
e
c
o
d
s
c
i
i
h
o
h
o
b
v
a
[
o
a
(
a
g
p
H
c
b
2
2
o
[
2
a
t
o
D
a
i
v
f
W
t
(
o
d
w
M
a
D
i
tM. Borggren et al. / Va
 crucial tool to beneﬁt swine health and reduce risks to public
ealth.
Current vaccines against inﬂuenza virus for pigs are based
n inactivated virus and only induce immunity against the virus
trains included in the vaccines, thus providing limited protec-
ion against the diverse spectrum of other circulating inﬂuenza
trains [1]. Thus, an effective intervention strategy for the control
f inﬂuenza in pigs requires improved vaccines. DNA technology
nables vaccination with versatile combinations of antigens that
an simply be substituted. The DNA platform was tested early
n in the inﬂuenza ﬁeld with variable results [4,5]. However, a
irect comparison between early results [6–8] and more recent
tudies are complicated due to recent improvements in DNA vac-
ines as well as the improved techniques to evaluate cell-mediated
mmune responses. Thus, codon-optimization of genes [9–14],
mproved delivery [12,15–17] and DNA vector improvements [18]
ave enhanced the immunogenicity of DNA vaccines, and a number
f DNA vaccine candidates have been successful in both animal and
uman studies [13–15,19–21]. DNA vaccines have the advantage
f inducing both cellular and humoral immunity, both of which are
elieved to serve important roles in protection against inﬂuenza
irus infections and shedding of virus [1,15,22].
Previously, we and others have tested DNA vaccines
gainst inﬂuenza in pigs in different experimental settings
6–8,15,20,23,24]. Recently, we published the optimization
f a polyvalent inﬂuenza DNA vaccine using next-generation
ntibiotic-free vectors together with a needle-free intradermal
i.d.) application in rabbits [25]. In the present study, we  conducted
 DNA dose titration study in pigs to investigate the immuno-
enicity of our optimized inﬂuenza DNA vaccine containing
andemic genes from the 1918 H1N1-, 1968 H3N2- and pdm09
1N1-inﬂuenza viruses. Thus, we tested the induction of both
ellular and humoral immune responses directed against antigens
oth homologous and heterologous to the vaccine.
. Materials and methods
.1. Construction of DNA vaccines
The six inﬂuenza DNA vaccine genes have been described previ-
usly [25]. The NTC9385R plasmid was used as an expression vector
18,25].
.2. Animals and experimental design
Twenty-two ﬁve-week-old, recently weaned pigs obtained from
 Danish speciﬁc pathogen free (SPF) herd were randomly assigned
o four groups of ﬁve or six animals. The pigs were housed with-
ut contact to other animals in separate isolation facilities at the
epartment of Animal Science, Aarhus University. The pigs were
llowed to acclimatize for 1 week before the initiation of the exper-
ment. With an interval of 3 weeks, three groups of pigs were
accinated twice on the dorsal site of the back using the needle-
ree IntraDermal Application of Liquids (IDAL®) device (Henke Sass
olf). Six pigs were vaccinated with 200 g of DNA each (one injec-
ion site on the back), another six pigs received 800 g of DNA each
distributed into four injection sites) and ﬁve pigs received 1972 g
f DNA (distributed into 10 injection sites). For use of the IDAL®
evice, the vaccine constructs were premixed at a 1:1 volume ratio
ith an -tocopherol-based aqueous solution (Diluvac Forte®,
SD  Animal Health). Two pigs remained unvaccinated, and threedditional pigs received the Diluvac Forte® solution without any
NA vaccine. The latter ﬁve pigs displayed similar immune proﬁles
n the analyses and were thus combined into the non-treated con-
rol group. All pigs were monitored daily for clinical signs of disease4 (2016) 3634–3640 3635
or any adverse vaccination-related effects. Rectal body tempera-
tures were recorded 2 days before and 2 days after each vaccination.
Whole-blood samples were collected from the anterior vena cava
of all pigs on days 0, 7, 14, 21, 28 and 35 post-ﬁrst vaccination (pv1).
Serum was  isolated and stored at -20 ◦C for subsequent examina-
tion. On day 35pv1, peripheral blood mononuclear cells (PBMC)
were isolated from freshly collected heparinized blood samples by
density gradient centrifugation and cryopreserved until use. On  a
weekly basis starting from day 0pv1, nasal swab (MicroRheolog-
ics) samples were collected in virus transport medium from all
pigs to test for potential accidental inﬂuenza infection during the
experiment. Upon termination of the experiment, on day 35pv1,
the pigs were euthanized by i.v. injection of a lethal dose of pento-
barbital. All animal handling and experimentation procedures were
approved by the Danish Animal Experiments Inspectorate (2014-
15-0201-00251).
2.3. Inﬂuenza detection
Nasal swab samples (day 0, 7, 14, 21, 28 and 35pv1) were exam-
ined for inﬂuenza A virus RNA using an in-house real-time reverse
transcription (RT)-PCR assay. Primers and probes for the matrix
gene of inﬂuenza A virus, the NA gene of H1N1pdm09 and the HA
gene of human seasonal H3N2 were used.
2.4. Enzyme-linked immunosorbent assay (ELISA)
ELISA was conducted to measure inﬂuenza-speciﬁc IgG
responses in the sera as previously described [25]. The inﬂuenza
virus proteins used for coating were HA from A/California/04/
09(H1N1)pdm09, A/Aichi/2/1968(H3N2), A/swine/Guangxi/13/
2006(H1N2) or A/Brisbane/59/07(H1N1); NA from A/Aichi/2/
1968(H3N2); NP from A/California/07/09(H1N1)pdm09; M1  pro-
tein from A/Brevig Mission/1/1918(H1N1) (all from Sino Biological
Inc.); or M2e  polypeptide (GenScript). A horseradish peroxidase-
conjugated anti-pig-IgG antibody (AbD Serotec) was  used for
detection.
2.5. Hemagglutination inhibition (HI) assay
The HI assay was performed according to the protocols of
the WHO  [26] as previously described [25]. The virus isolates
tested were two swine strains, A/swine/Denmark (DK)/10409/
2013(H1N1pdm) and A/swine/DK/10525/2008(H1N2).
2.6. Microneutralization assay (MN)
Development of neutralizing antibodies was  determined
according to the protocols of the WHO  [27]. Viruses used were
A/California/07/09(H1N1pdm09), A/NewCaledonia/20/99(H1N1),
and A/swine/DK/10409/2013(H1N1pdm), with 100 TCID50 as the
inoculum.
2.7. PBMC stimulation and cell-mediated immune assays
Prior to stimulation, the cryopreserved PBMC were thawed and
rested overnight in R10 (RPMI, Gibco) supplemented with 10% heat-
inactivated FBS (Gibco) and 1% penicillin–streptomycin (Gibco)
(culture medium) at 37 ◦C with 5% CO2. During stimulation, the R10
was supplemented with 50 ng/ml porcine IL-18 (R&D). The PBMC
were stimulated with 5 g/ml recombinant inﬂuenza proteins,
including NP from A/California/07/09(H1N1)pdm09 and A/Brevig
Mission/1/1918(H1N1), HA from A/California/04/09(H1N1)pdm09
or matrix 1 (M1) from A/Brevig Mission/1/1918(H1N1) (all from
Sino Biological Inc.). One microgram per milliliter Staphylococ-
cus Enterotoxin B (SEB, Sigma) served as a positive control
and media alone served as a negative control. After 18 h of
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timulation, 10 g/ml Brefeldin A (Sigma) was added, followed
y an additional 6 h of incubation. The stimulation was  halted
y 2 mM EDTA. The cells were stained with anti-CD3 PE-Cy7 (BD
harmingen), anti-CD4 FITC (Serotec), anti-CD8 PE (Serotec) and a
iolet dead cell staining kit (Invitrogen), ﬁxed and permeabilized
ith Cytoﬁx/Cytoperm (BD) and stained with anti-IFN- AF647
Serotec). The stained cells were acquired using a BD LSRII and ana-
yzed using FlowJo (Tree Star). The background level of cytokine
taining in the non-stimulated samples was subtracted for each
ndividual animal. For the assessment of cell proliferation, in com-
ination with the IFN- response, PBMC were labeled with 5 M
ellTrace Violet (Molecular probes), as described by the manu-
acturer, prior to stimulation. The cells were suspended in R10
upplemented with IL-18 and 50 M 2-mercaptoethanol (Sigma)
nd stimulated for 5 days with 2 g/ml of recombinant inﬂuenza
roteins. At day 5, the PBMC were re-stimulated with the same
mount of proteins for an additional 18 h. Next, 10 g/ml Brefeldin
 was added, followed by an additional 6 h of incubation. The cells
ere stained and acquired as described above but with the near IR
ead cell staining kit (Invitrogen).
.8. Statistical analysis
Differences between the groups were calculated using two-way
NOVA and Bonferroni multiple comparison test (GraphPad Prism
.6, GraphPad software).
. Results.1. Clinical observations
None of the pigs displayed any signs of clinical disease or side
ffects of vaccination during the experiment. In addition, inﬂuenza
ig. 1. Inﬂuenza-speciﬁc antibody response following DNA vaccination. Pigs were vaccin
r  1972 g (n = 5) DNA, or not DNA vaccinated at all (n = 5). Levels of IgG in the sera were
o  the vaccine or (e-h) heterologous to the vaccine were used as the coating antigens. All 
ndicate the mean ± SEM, and signiﬁcant differences from the no-vaccine control group a4 (2016) 3634–3640
virus could not be identiﬁed in any of the weekly collected nasal
secretions.
3.2. Induction of cross-reactive antibodies
Antibody responses against three out of the four tested differ-
ent inﬂuenza proteins, homologous to the vaccine genes, could be
detected in the vaccinated pigs (Fig. 1a−d). In particular, the HA-
speciﬁc antibodies were found to be present at high titers after
day 28pv1, and anti-H3 antibodies were detected at day 14pv1.
The antibody response levels correlated well with the applied DNA
doses. In addition, antibody responses against inﬂuenza proteins
not corresponding to the vaccine genes were detected (Fig. 1e−h).
Antibodies against recombinant HA of both human and swine ori-
gin (Fig. 1e,f) were seen after day 28pv1 in the two pig groups
receiving the highest DNA doses. A high antibody response was
detected against NP originating from H1N1pdm09 in all vacci-
nated groups. Both vaccinated and control pigs had low levels of
inﬂuenza-speciﬁc IgG against several different antigens at day 0pv1
(Fig. 1a H1pdm09, 1C N2 1968, 1E H1 2007 and 1G NPpdm09).
This low level detected at day 0 gradually deceased over time in
the control group, thus indicating that these antibodies represent
maternally derived antibodies (MDA).
3.3. Induction of HI antibodies
Vaccinated pigs had vaccine-induced serum HI antibodies that
were cross-reactive against two  swine virus strains, H1N1pdm09
and H1N2, which were heterologous to the vaccine genes (Fig. 2).
The HI antibody levels were signiﬁcantly higher in the group vac-
cinated with the highest dose of DNA than in the control group
after day 28pv1. The HI titers obtained with the two  different virus
ated twice (arrows) i.d. with needle-free delivery with 200 g (n = 6), 800 g (n = 6)
 measured by ELISA. Recombinant inﬂuenza proteins that were (a-d) homologous
serum samples were tested using a ﬁxed 1:100 or 1:125 serum dilution. Error bars
re indicated by: ****: p < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05.
M. Borggren et al. / Vaccine 34 (2016) 3634–3640 3637
Fig. 2. Serum HI antibody titers in vaccinated pigs. Pigs were vaccinated twice (arrows) i.d. with needle-free delivery with 200 g (n = 6), 800 g (n = 6) or 1972 g (n = 5)
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rom  the no-vaccine control group are indicated by: ****: p < 0.0001; *: p < 0.05.
trains correlated signiﬁcantly with each other (Spearman correla-
ion, r = 0.50, p < 0.0001).
.4. Induction of neutralizing activity
Neutralizing activity against H1N1 virus strains, both homol-
gous and heterologous to the vaccine genes, developed in the
accinated pigs (Fig. 3, only day 21 and beyond are shown). Neu-
ralization could not be detected at time points earlier than day
8pv1, i.e. 1 week after the second vaccination. At this stage, the
igs receiving the highest dose of DNA had developed signiﬁ-
antly higher MN  titers against the homologous inﬂuenza virus
1N1pdm09 (Fig. 3a) and a heterologous human isolate (Fig. 3b)
han the control group. At day 35pv1, the pigs given the middle
ose of DNA, 800 g, also had elevated MN titers against both
uman H1N1 isolates. Neutralization of a heterologous swine virus,
1N1pdm09, was also detected in the vaccinated pigs on day 35pv1
Fig. 3c). Notably, only the lower- and middle-dose DNA groups
emonstrated signiﬁcant levels of neutralization compared to the
ontrol group. Signiﬁcant correlations were observed for the MN
iters derived from the three virus strains tested (Spearman corre-
ations for all combinations between the three virus strains, r-range
.45−0.64, p range 0.0001 to < 0.0001).
.5. Induction of antigen-speciﬁc T cell responsesThe DNA vaccine elicited NP-, M1-  and HA-speciﬁc CD4-CD8+
 cells and CD4+CD8+T cells producing IFN- (Fig. 4a and b). The
FN- response levels correlated with the DNA vaccine doses. Both
ig. 3. Neutralizing activity in vaccinated pig sera. Pigs were vaccinated twice (day 0 and
n  = 5) DNA, or not DNA vaccinated at all (n = 5). The pig sera were tested in a microneutr
ere  evaluated by the capacity of the sera to prevent the infection of MDCK cells by (a) H
s  the reciprocal dilution giving 50% infection inhibition and calculated with a linear int
he  assay (lowest serum dilution tested was  1:20) were assigned a value of 10 for graphic
igniﬁcant differences from the no-vaccine control group are indicated by: ***: p < 0.001; ntibody responses in pig sera against (a) swine H1N1pdm09 and (b) swine H1N2
 of two  performed. Error bars indicate the mean ± SEM, and signiﬁcant differences
vaccine-homologous and vaccine-heterologous NP (1918 and 2009,
respectively) could re-stimulate the PBMC, and their respective
IFN- responses correlated signiﬁcantly (r = 0.78, p < 0.0001 (Spear-
man  correlation) for CD4-CD8+ T cells and r = 0.86, p < 0.0001 for
CD4+CD8+T cells.) CD4+CD8-T cells contained lower levels of re-
stimulated cells (Fig. 4c). A similar pattern was observed when the
proliferation level of re-stimulated PBMC was assessed (Fig. 5). Pigs
receiving the highest dose of the vaccine had a proliferating recall
response signiﬁcantly higher than the control group. The expres-
sion of IFN- coincided with proliferating cells; the mean for all
groups was 64.4% (standard deviation, 14.8) of proliferating cells
also expressing IFN-.
4. Discussion
In the present study, we demonstrated that our polyvalent DNA
inﬂuenza vaccine delivered via needle-free i.d. application induced
a signiﬁcant immune response against homologous as well as het-
erologous inﬂuenza antigens, represented by both antibody- and
cell-mediated reactivity. The vaccine responses correlated with
the DNA doses, i.e. higher responses with increasing DNA doses.
The intermediate dose of 800 g DNA/vaccination seemed to be
almost as effective as the highest dose of 1972 g DNA, and
even the lowest dose of 200 g DNA/vaccination could induce a
detectable response. However, the protective effect of the various
doses requires further challenge studies.
The highest dose of DNA in this study was  chosen to be
equimolar to the dosage used in our previous pig challenge study
[20], where pigs vaccinated via i.d. needle and electroporation
 21 pv1) i.d. with needle-free delivery with 200 g (n = 6), 800 g (n = 6) or 1972 g
alization assay on days 21, 28 and 35 pv1. Neutralizing antibody titers, MN titers,
1N1pdm09, (b) 1999 H1N1 and (c) swine H1N1 isolates. The MN titer was deﬁned
erpolation method [28]. Serum samples with a titer below the detectable limit of
al representation and statistical analyses. Error bars indicate the mean ± SEM, and
**: p < 0.01; *: p < 0.05.
3638 M. Borggren et al. / Vaccine 34 (2016) 3634–3640
Fig. 4. T cell sub-population IFN- response to in vitro re-stimulation with inﬂuenza proteins. Pigs were vaccinated twice (day 0 and 21pv1) i.d. with needle-free delivery
with  200 g (n = 6), 800 g (n = 6) or 1972 g (n = 5) DNA, or not DNA vaccinated at all (n = 5). PBMC from the vaccinated pigs on day 35pv1 were cultured in vitro in the
presence of recombinant inﬂuenza NP 2009, NP 1918, M1  1918 and HA 2009. After 24 h, the cells were stained with anti-CD3, -CD4, -CD8 and -IFN- monoclonal antibodies
and  analyzed by ﬂow cytometry. Three T cell subsets were identiﬁed based on their CD4 and CD8 expression: (a) CD4-CD8+, (b) CD4+CD8+ and (c) CD4+CD8- cells. Error bars
indicate the mean ± SEM, and signiﬁcant differences from the no-vaccine control group are indicated by: ***: p < 0.001; **: p < 0.01; *: p < 0.05.
Fig. 5. T cell sub-population proliferation response to in vitro re-stimulation with inﬂuenza proteins. Pigs were vaccinated twice (day 0 and 21pv1) i.d. with needle-free
delivery with 200 g (n = 6), 800 g (n = 6) or 1972 g (n = 5) DNA, or not DNA vaccinated at all (n = 5). PBMC from the vaccinated pigs on day 35pv1 were cultured in vitro in
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nd  analyzed by ﬂow cytometry. Three T cell subsets were identiﬁed based on their
ndicate the mean ± SEM, and signiﬁcant differences from the no-vaccine control gr
emonstrated protective immunity, as measured by reduced viral
hedding after challenge. Similar to our previous study [20], Gorres
t al. [15] also demonstrated reduced virus shedding with a com-
arable amount of DNA in a pig challenge study. The results of the
resent study suggest that the DNA dose can be reduced to less
han half amount of plasmid compared to our previous challenge
tudy [20] and still maintain immunogenicity. Moreover, we have
emoved the antibiotic resistance selection in the plasmid to avoid
nterference with antibiotics used in the pig industry [18].
Humoral immune response analyses revealed an antibody
esponse after the ﬁrst vaccination that was boosted after re-
accination. In addition to a homologous response, vaccination
ith our polyvalent DNA vaccine appears to induce broadly reac-
ive antibodies against multiple H1N1 and H1N2 strains of human
nd swine origin. Because our DNA vaccine encodes four different
nﬂuenzas surface-exposed glycoproteins, H1, N1, H3 and N2, we
xpected to detect a heterogeneous antibody response against sev-
ral inﬂuenza strains. HA-speciﬁc antibodies are of importance for
accine efﬁcacy because they can provide protection by blocking
irus attachment and entry [28]. In addition, NA-speciﬁc antibod-
es have been shown to reduce virus shedding and decrease severe
llness (reviewed by Marcelin et al. [29]). The NP plasmid was
ncluded to induce cellular immunity to NP proteins, which are
elatively constant among different inﬂuenza virus strains [30].
owever, the in vivo-encoded NP also gave rise to high antibody
iters that are not expected to prevent viral entry because NP is
ot exposed on the surface of the virion [31,32]. The M protein
s a relatively constant protein with an extracellular surface loop, days, the cells were stained with anti-CD3, -CD4, and -CD8 monoclonal antibodies
nd CD8 expression: (a) CD4-CD8+, (b) CD4+CD8+ and (c) CD4+CD8- cells. Error bars
re indicated by: **: p < 0.01; *: p < 0.05.
M2e, which is exposed to antibodies [33]. Thus, antibodies against
M may  be cross-protective against different inﬂuenza strains [34].
Indeed, we did observe anti-M2e-speciﬁc antibodies in vaccinated
pigs, which potentially can serve a protective role during infec-
tion. The combination of antibodies against both conserved (NP
and M2e) and more diverse inﬂuenza antigens (HA and NA) suggest
a potent cross-reactive IgG response generated by our polyvalent
DNA vaccine. Indeed, the cross-reactive response was  reﬂected
in the functional humoral hemagglutination inhibition and neu-
tralization assays. Both of these assays demonstrated a vaccine
response against circulating swine inﬂuenza isolates that were het-
erologous to our vaccine, which is promising for a future swine
vaccine. In addition, the HI and MN  titers were correlated between
the different virus strains tested, indicating that the induced anti-
body response is cross-reactive.
Cellular immune responses play an important role during
inﬂuenza infection by contributing to eliminate infected cells and
reduce virus shedding [35], and DNA vaccines have the advantage
of inducing both a humoral and a cellular immune response [36,37].
While Gorres et al. [15] could not detect signiﬁcant levels of IFN-
secreting cells after needle-free (subcutaneous (s.c.)/i.m.) vaccina-
tion with a DNA inﬂuenza vaccine, we demonstrated signiﬁcant
dose-related levels of IFN--producing T cells against inﬂuenza
virus speciﬁc proteins 2 weeks after the second needle-free i.d.
vaccination. A number of factors related to the different analysis
methods may  explain this discrepancy, but it may  also under-
line the superiority of i.d. compared to s.c./i.m. application. In our
assay, both the NP 1918 and M1  1918 proteins, homologous to the
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NA vaccine, could re-stimulate the T cells. In addition, a NP pro-
ein from the pdm09 virus strain could also stimulate the T cell
esponse, which indicates that the NP-speciﬁc T cell response is
ross-reactive. Moreover, there also seems to be a T cell response
gainst the externally expressed proteins, represented by HA pro-
ein in our assay. The functionality of an inﬂuenza-speciﬁc T cell
esponse, including proliferation and degranulation, has previously
een published to correlate with IFN--production [38], which was
lso conﬁrmed herein. Although the humoral response, especially
he HA-speciﬁc response, may  be the primary factor in inﬂuenza
rotection, other studies have suggested the importance of cell-
ediated immunity in pigs and ferrets upon DNA vaccination
ollowed by challenge [15,23,39]. Thus, the present conﬁrmation
f the vaccine-induced IFN- response in T cells to coincide with
roliferation indicates that our i.d.-applied DNA vaccine provokes
 speciﬁc cell-mediated response, which may  provide strong con-
ribute to heterotypic inﬂuenza immunity [40–42].
Vaccination of piglets with MDA  using a conventional inﬂuenza
accine may  have potential complications such as the suppression
f the immune response [43–45] and the induction of vaccine-
ssociated enhanced respiratory disease (VAERD) [45,46]. Our
esults demonstrating the development of antibody responses in
igs with MDA  support previous ﬁndings indicating the ability of
he DNA vaccine to function in the presence of MDA  [47]. This abil-
ty of DNA vaccines represents a major advantage of using a DNA
accine approach in the inﬂuenza vaccination of swine herds.
We believe that our approach of using pandemic-derived sur-
ace inﬂuenza antigens with conserved internal antigens has the
bility to confer broad protection against both homologous and het-
rologous virus strains, with both antibody and T cell responses as
ontributors. Furthermore, the lack of adverse reactions to vaccina-
ion indicates that the vaccine is safe for the animals. The possibility
o deliver the DNA vaccine using a needle-free approach is a realistic
nd attractive alternative for convenient, safe and animal welfare-
riendly mass vaccination in swine herds, a method already in use
or traditional protein vaccines in pigs. The present results encour-
ge inﬂuenza challenge studies with a lower dose of DNA than used
reviously [20] to demonstrate the efﬁcacy of the polyvalent DNA
accine, thus paving the way for an improved intervention strategy
n the ﬁght against inﬂuenza.
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